GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lasa Supergenerics Ltd (BOM:540702) » Definitions » EV-to-EBIT

Lasa Supergenerics (BOM:540702) EV-to-EBIT : -8.72 (As of Dec. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Lasa Supergenerics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lasa Supergenerics's Enterprise Value is ₹1,574 Mil. Lasa Supergenerics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-181 Mil. Therefore, Lasa Supergenerics's EV-to-EBIT for today is -8.72.

The historical rank and industry rank for Lasa Supergenerics's EV-to-EBIT or its related term are showing as below:

BOM:540702' s EV-to-EBIT Range Over the Past 10 Years
Min: -344.98   Med: -2.67   Max: 48.51
Current: -8.72

During the past 9 years, the highest EV-to-EBIT of Lasa Supergenerics was 48.51. The lowest was -344.98. And the median was -2.67.

BOM:540702's EV-to-EBIT is ranked worse than
100% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs BOM:540702: -8.72

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Lasa Supergenerics's Enterprise Value for the quarter that ended in Sep. 2024 was ₹1,637 Mil. Lasa Supergenerics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-181 Mil. Lasa Supergenerics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -11.03%.


Lasa Supergenerics EV-to-EBIT Historical Data

The historical data trend for Lasa Supergenerics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lasa Supergenerics EV-to-EBIT Chart

Lasa Supergenerics Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only 13.42 8.30 -28.22 -2.94 -7.68

Lasa Supergenerics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.49 -7.30 -7.68 -5.95 -9.07

Competitive Comparison of Lasa Supergenerics's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Lasa Supergenerics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lasa Supergenerics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lasa Supergenerics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lasa Supergenerics's EV-to-EBIT falls into.



Lasa Supergenerics EV-to-EBIT Calculation

Lasa Supergenerics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1574.375/-180.521
=-8.72

Lasa Supergenerics's current Enterprise Value is ₹1,574 Mil.
Lasa Supergenerics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-181 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lasa Supergenerics  (BOM:540702) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Lasa Supergenerics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=-180.521/1637.000632
=-11.03 %

Lasa Supergenerics's Enterprise Value for the quarter that ended in Sep. 2024 was ₹1,637 Mil.
Lasa Supergenerics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-181 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lasa Supergenerics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Lasa Supergenerics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Lasa Supergenerics Business Description

Traded in Other Exchanges
Address
Plot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Khed Taluka, Ratnagiri, MH, IND, 415722
Lasa Supergenerics Ltd is engaged in the research, manufacturing, trading, producing, processing, preparing, and treating chemicals, API, Pharmaceuticals, drugs, and others. The company specializes in catalyst chemistry and manufactures anthelmintic and veterinary API products.

Lasa Supergenerics Headlines

No Headlines